Significant differences in T stage, histological subtype, histological grade, Ki67, TOPIIa, and surgical modality were found between the HER2 IHC 1+ and HER2 IHC 2+ plus ISH− BC patient groups (p < 0.05; Table 3). This evidence concerns the gene ERBB2 and breast cancer.